GO
| HSI1 | 25,962.73 | -426.31 | 325.39B |
| HSCEI1 | 8,691.03 | -167.60 | 91.91B |
| Back Zoom + Zoom - Block Traded | |
|
SBP GROUP Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity
2026-05-14 09:24:30 SBP GROUP (01177.HK) announced that preclinical research data for TQF6422 “ActRII A/B Monoclonal Antibody”, an innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of the Company, has been presented at European Congress on Obesity 2026 (ECO). TQF6422 is a fully human monoclonal antibody targeting ActRII A/B. By specifically binding to the ActRII A/B receptors and blocking transduction of ligand-mediated signaling involving Activin or Myostatin, it promotes skeletal muscle growth while enhancing lipolysis, thereby achieving the dual effect of fat loss and muscle gain. ~ AASTOCKS Financial News Website: www.aastocks.com | |